Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Gross Margin (2016 - 2018)

Theravance Biopharma (TBPH) has disclosed Gross Margin for 6 consecutive years, with 90.07% as the latest value for Q1 2018.

  • Quarterly Gross Margin rose 837.0% to 90.07% in Q1 2018 from the year-ago period, while the trailing twelve-month figure was 69.49% through Mar 2018, down 2247.0% year-over-year, with the annual reading at 60.81% for FY2017, 1990.0% down from the prior year.
  • Gross Margin for Q1 2018 was 90.07% at Theravance Biopharma, up from 30.99% in the prior quarter.
  • The five-year high for Gross Margin was 98.26% in Q3 2016, with the low at 124.84% in Q4 2014.
  • Average Gross Margin over 5 years is 67.45%, with a median of 88.34% recorded in 2016.
  • The sharpest move saw Gross Margin plummeted -22484bps in 2014, then surged 14262bps in 2015.
  • Over 5 years, Gross Margin stood at 124.84% in 2014, then surged by 114bps to 17.78% in 2015, then soared by 349bps to 79.87% in 2016, then crashed by -61bps to 30.99% in 2017, then surged by 191bps to 90.07% in 2018.
  • According to Business Quant data, Gross Margin over the past three periods came in at 90.07%, 30.99%, and 76.96% for Q1 2018, Q4 2017, and Q3 2017 respectively.